List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5464154/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. Tumori, 2023, 109, 112-120.	0.6	3
2	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	0.8	8
3	Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes. Strahlentherapie Und Onkologie, 2022, 198, 56-65.	1.0	8
4	Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. International Journal of Radiation Oncology Biology Physics, 2022, 112, 499-513.	0.4	10
5	Combined DNA Damage Repair Interference and Ion Beam Therapy: Development, Benchmark, and Clinical Implications of a Mechanistic Biological Model. International Journal of Radiation Oncology Biology Physics, 2022, 112, 802-817.	0.4	6
6	High omplexity cellular barcoding and clonal tracing reveals stochastic and deterministic parameters of radiation resistance. International Journal of Cancer, 2022, 150, 663-677.	2.3	3
7	Dualâ€layer spectral CT for proton, helium, and carbon ion beam therapy planning of brain tumors. Journal of Applied Clinical Medical Physics, 2022, 23, .	0.8	3
8	Human mesenchymal stromal cells maintain their stem cell traits after high-LET particle irradiation – Potential implications for particle radiotherapy and manned space missions. Cancer Letters, 2022, 524, 172-181.	3.2	2
9	Ultra-High Dose Rate (FLASH) Carbon Ion Irradiation:ÂDosimetry and First Cell Experiments. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1012-1022.	0.4	39
10	Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation. International Journal of Gynecological Cancer, 2022, 32, 172-180.	1.2	2
11	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
12	Influence of photon, proton and carbon ion irradiation on differentiation, maturation and functionality of dendritic cells. Frontiers in Bioscience - Scholar, 2022, 14, 1.	0.8	5
13	Quality assurance for onâ€ŧable adaptive magnetic resonance guided radiation therapy: A software tool to complement secondary dose calculation and failure modes discovered in clinical routine. Journal of Applied Clinical Medical Physics, 2022, 23, e13523.	0.8	14
14	Deep Learning–based Automatic Lung Segmentation on Multiresolution CT Scans from Healthy and Fibrotic Lungs in Mice. Radiology: Artificial Intelligence, 2022, 4, e210095.	3.0	6
15	Radiation induced contrast enhancement after proton beam therapy in patients with low grade glioma – How safe are protons?. Radiotherapy and Oncology, 2022, 167, 211-218.	0.3	27
16	SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. Radiotherapy and Oncology, 2022, 168, 106-112.	0.3	10
17	How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine. Radiation Oncology, 2022, 17, 23.	1.2	4
18	Neuroprotective Effects of Ultra-High Dose Rate FLASH Bragg Peak Proton Irradiation. International Journal of Radiation Oncology Biology Physics, 2022, 113, 614-623.	0.4	13

#	Article	IF	CITATIONS
19	Biosensor for deconvolution of individual cell fate in response to ion beam irradiation. Cell Reports Methods, 2022, 2, 100169.	1.4	1
20	The Impact of Sub-Millisecond Damage Fixation Kinetics on the In Vitro Sparing Effect at Ultra-High Dose Rate in UNIVERSE. International Journal of Molecular Sciences, 2022, 23, 2954.	1.8	6
21	Relative biological effectiveness of single and split helium ion doses in the rat spinal cord increases strongly with linear energy transfer. Radiotherapy and Oncology, 2022, 170, 224-230.	0.3	5
22	Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Science Advances, 2022, 8, eabh4050.	4.7	55
23	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
24	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology, 2022, 34, 15-22.	0.9	6
25	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Oncolmmunology, 2022, 11, 2066609.	2.1	13
26	Potential of a Second-Generation Dual-Layer Spectral CT for Dose Calculation in Particle Therapy Treatment Planning. Frontiers in Oncology, 2022, 12, 853495.	1.3	5
27	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
28	Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Cancers, 2022, 14, 2409.	1.7	2
29	Return to Work, Fatigue and Cancer Rehabilitation after Curative Radiotherapy and Radiochemotherapy for Pelvic Gynecologic Cancer. Cancers, 2022, 14, 2330.	1.7	3
30	Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults. Radiotherapy and Oncology, 2022, 172, 54-64.	0.3	9
31	Biological Dose Optimization for Particle Arc Therapy Using Helium and Carbon Ions. International Journal of Radiation Oncology Biology Physics, 2022, 114, 334-348.	0.4	6
32	EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma. Neuro-Oncology, 2022, 24, i41-i41.	0.6	0
33	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 143-151.	3.3	25
34	Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). International Journal of Radiation Oncology Biology Physics, 2021, 109, 1311-1324.	0.4	37
35	Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma. Radiotherapy and Oncology, 2021, 155, 293-303.	0.3	5
36	Impact of ⁶⁸ Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. Journal of Nuclear Medicine, 2021, 62, 779-786.	2.8	113

#	Article	IF	CITATIONS
37	Diagnostic Accuracy of ¹⁸ F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. Journal of Nuclear Medicine, 2021, 62, 208-213.	2.8	77
38	Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil. Strahlentherapie Und Onkologie, 2021, 197, 644-649.	1.0	5
39	Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. Cancers, 2021, 13, 124.	1.7	1
40	MR-guided radiotherapy of moving targets. Der Radiologe, 2021, 61, 39-48.	1.7	6
41	<i>In Vivo</i> Evaluation of Combined CK2 Inhibition and Irradiation in Human WiDr Tumours. In Vivo, 2021, 35, 111-117.	0.6	1
42	A practical implementation of risk management for the clinical introduction of online adaptive Magnetic Resonance-guided radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 17, 53-57.	1.2	28
43	How can scanned proton beam treatment planning for lowâ€grade glioma cope with increased distal RBE and locally increased radiosensitivity for late MRâ€detected brain lesions?. Medical Physics, 2021, 48, 1497-1507.	1.6	17
44	Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review. EJNMMI Research, 2021, 11, 18.	1.1	33
45	X-change symposium: status and future of modern radiation oncology—from technology to biology. Radiation Oncology, 2021, 16, 27.	1.2	1
46	modelBuildR: an R package for model building and feature selection with erroneous classifications. PeerJ, 2021, 9, e10849.	0.9	3
47	Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Cancers, 2021, 13, 796.	1.7	32
48	Individualized 3D-Printed Tissue Retraction Devices for Head and Neck Radiotherapy. Frontiers in Oncology, 2021, 11, 628743.	1.3	7
49	Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy – Results from a large multicenter analysis. Radiotherapy and Oncology, 2021, 156, 266-274.	0.3	7
50	Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-NaÃ⁻ve Prostate Carcinoma. Cancers, 2021, 13, 1508.	1.7	8
51	[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3011-3013.	3.3	60
52	3D-printed individualized tooth-borne tissue retraction devices compared to conventional dental splints for head and neck cancer radiotherapy: a randomized controlled trial. Radiation Oncology, 2021, 16, 75.	1.2	5
53	Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge. Anticancer Research, 2021, 41, 1909-1920.	0.5	3
54	PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme Journal of Clinical Oncology, 2021, 39, 2041-2041.	0.8	1

#	Article	IF	CITATIONS
55	Effectiveness of fractionated carbon ion treatments in three rat prostate tumors differing in growth rate, differentiation and hypoxia. Radiotherapy and Oncology, 2021, 158, 131-137.	0.3	2
56	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters, 2021, 506, 1-10.	3.2	17
57	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	3.2	9
58	68Ga-FAPI-PET/CT in patients with various gynecological malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4089-4100.	3.3	91
59	The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiotherapy and Oncology, 2021, 159, 8-16.	0.3	21
60	Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes. Frontiers in Oncology, 2021, 11, 610637.	1.3	31
61	Deciphering Time-Dependent DNA Damage Complexity, Repair, and Oxygen Tension: A Mechanistic Model for FLASH-Dose-Rate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 574-586.	0.4	19
62	Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 708884.	1.3	5
63	68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. Radiotherapy and Oncology, 2021, 160, 192-201.	0.3	40
64	FLASH Dose Rate Helium Ion Beams: First In Vitro Investigations. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1011-1022.	0.4	34
65	Neurocognitive Outcomes in Pediatric Patients Following Brain Irradiation. Cancers, 2021, 13, 3538.	1.7	12
66	Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study. BMC Cancer, 2021, 21, 812.	1.1	9
67	Low-dose radiotherapy for painful osteoarthritis of the elderly: AÂmulticenter analysis of 970Âpatients with 1185 treated sites. Strahlentherapie Und Onkologie, 2021, 197, 895-902.	1.0	6
68	Two Tumors, One Target. Clinical Nuclear Medicine, 2021, 46, 842-844.	0.7	30
69	Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. Strahlentherapie Und Onkologie, 2021, , 1.	1.0	5
70	18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 26.	1.8	38
71	Simultaneous targeting of TGF- \hat{I}^2 /PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell, 2021, 39, 1388-1403.e10.	7.7	92
72	Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nature Reviews Physics, 2021, 3, 777-790.	11.9	47

#	Article	IF	CITATIONS
73	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. Radiotherapy and Oncology, 2021, 163, 165-176.	0.3	7
74	Carbon Ion Radiation Therapy: One Decade of Research and Clinical Experience at Heidelberg Ion Beam Therapy Center. International Journal of Radiation Oncology Biology Physics, 2021, 111, 597-609.	0.4	10
75	Spinal Stabilization Exercises for Cancer Patients with Spinal Metastases of High Fracture Risk: Feasibility of the DISPO-II Training Program. Cancers, 2021, 13, 201.	1.7	9
76	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
77	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	5.9	52
78	DCE-MRI detected vascular permeability changes in the rat spinal cord do not explain shorter latency times for paresis after carbon ions relative to photons. Radiotherapy and Oncology, 2021, 165, 126-134.	0.3	2
79	Effectiveness and Toxicity of Fractionated Proton Beam Radiotherapy for Cranial Nerve Schwannoma Unsuitable for Stereotactic Radiosurgery. Frontiers in Oncology, 2021, 11, 772831.	1.3	5
80	Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience. Radiology and Oncology, 2021, 55, 467-473.	0.6	5
81	Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients. Frontiers in Neuroscience, 2021, 15, 782516.	1.4	6
82	Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations. Frontiers in Oncology, 2021, 11, 757031.	1.3	17
83	Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study. Frontiers in Psychology, 2021, 12, 760024.	1.1	1
84	Postoperative Radiotherapy for Endometrial Cancer in Elderly (≥80 Years) Patients: Oncologic Outcomes, Toxicity, and Validation of Prognostic Scores. Cancers, 2021, 13, 6264.	1.7	2
85	Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy—GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study. Radiation Oncology, 2021, 16. 240.	1.2	4
86	Development and Validation of Single Field Multi-Ion Particle Therapy Treatments. International Journal of Radiation Oncology Biology Physics, 2020, 106, 194-205.	0.4	43
87	The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2020, 106, 167-173.	0.4	18
88	Lymph Node Involvement in Treatment-NaÃ ⁻ ve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. Journal of Nuclear Medicine, 2020, 61, 46-50.	2.8	26
89	Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies. British Journal of Radiology, 2020, 93, 20190516.	1.0	28
90	Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. European Journal of Surgical Oncology, 2020, 46, 905-913.	0.5	8

#	Article	IF	CITATIONS
91	Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin. Strahlentherapie Und Onkologie, 2020, 196, 515-521.	1.0	13
92	Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study. BMC Cancer, 2020, 20, 947.	1.1	12
93	Feasibility of Optical Surface-Guidance for Position Verification and Monitoring of Stereotactic Body Radiotherapy in Deep-Inspiration Breath-Hold. Frontiers in Oncology, 2020, 10, 573279.	1.3	21
94	An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC Medical Research Methodology, 2020, 20, 257.	1.4	41
95	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors. Cancers, 2020, 12, 2862.	1.7	3
96	Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients. NeuroImage: Clinical, 2020, 28, 102427.	1.4	22
97	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates. Frontiers in Oncology, 2020, 10, 586449.	1.3	15
98	Large German Multicenter Experience on the Treatment Outcome of 207 Patients With Adenoid Cystic Carcinoma of the Major Salivary Glands. Frontiers in Oncology, 2020, 10, 593379.	1.3	7
99	Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. Radiation Oncology, 2020, 15, 190.	1.2	10
100	Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 776-783.	0.6	1
101	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiation Oncology, 2020, 15, 235.	1.2	13
102	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. Frontiers in Oncology, 2020, 10, 592796.	1.3	10
103	Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool. Frontiers in Oncology, 2020, 10, 1557.	1.3	4
104	A treatment planning study of combined carbon ion-beam plus photon intensity-modulated radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 16-22.	1.2	3
105	High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: long-term clinical results of a single particle therapy center. Radiation Oncology, 2020, 15, 206.	1.2	10
106	Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. Cancers, 2020, 12, 2629.	1.7	37
107	Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer—A Single-Center Experience and Review of the Literature. Cancers, 2020, 12, 2301.	1.7	5
108	Particle therapy in the future of precision therapy. British Journal of Radiology, 2020, 93, 20200183.	1.0	27

#	Article	IF	CITATIONS
109	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Clinical Lung Cancer, 2020, 22, 332-340.e3.	1.1	11
110	Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines. Scientific Reports, 2020, 10, 21517.	1.6	13
111	Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. Frontiers in Oncology, 2020, 10, 564857.	1.3	19
112	Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?. Cancers, 2020, 12, 3645.	1.7	1
113	Lack of Relevant Haemogram Changes During Percutaneous Radiotherapy of Localised Prostate Cancer. In Vivo, 2020, 34, 1555-1563.	0.6	0
114	RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	0.9	16
115	Modeling Direct and Indirect Action on Cell Survival After Photon Irradiation under Normoxia and Hypoxia. International Journal of Molecular Sciences, 2020, 21, 3471.	1.8	10
116	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlentherapie Und Onkologie, 2020, 196, 705-714.	1.0	8
117	Single-Isocenter Volumetric Modulated Arc Therapy vs. CyberKnife M6 for the Stereotactic Radiosurgery of Multiple Brain Metastases. Frontiers in Oncology, 2020, 10, 568.	1.3	14
118	Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection—Outcome, Prognostic Factors, and Recurrence Patterns. Frontiers in Oncology, 2020, 10, 693.	1.3	11
119	Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Radiotherapy and Oncology, 2020, 147, 145-150.	0.3	31
120	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of aÂrandomized phaseÂ2 trial (LEOPARD-2). Strahlentherapie Und Onkologie, 2020, 196, 795-804.	1.0	9
121	Late Contrast Enhancing Brain Lesions in Proton-Treated Patients With Low-Grade Glioma: Clinical Evidence for Increased Periventricular Sensitivity and Variable RBE. International Journal of Radiation Oncology Biology Physics, 2020, 107, 571-578.	0.4	83
122	Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). Radiation Oncology, 2020, 15, 134.	1.2	5
123	Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. Cancers, 2020, 12, 676.	1.7	12
124	Design and Development of ^{99m} Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸ Re Therapy. Journal of Nuclear Medicine, 2020, 61, 1507-1513.	2.8	110
125	Assessment of RBE-Weighted Dose Models for Carbon Ion Therapy Toward Modernization of Clinical Practice at HIT: InÂVitro, inÂVivo, and in Patients. International Journal of Radiation Oncology Biology Physics, 2020, 108, 779-791.	0.4	39
126	Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiotherapy and Oncology, 2020, 150, 159-163.	0.3	47

JüRGEN DEBUS

#	Article	IF	CITATIONS
127	Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. Frontiers in Oncology, 2020, 10, 987.	1.3	19
128	Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Frontiers in Oncology, 2020, 10, 989.	1.3	15
129	Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiation Oncology, 2020, 15, 30.	1.2	36
130	<p>Percutaneous Endoscopic Gastrostomy Tube Placement in Patients with Head and Neck Cancer Treated with Radiotherapy</p> . Cancer Management and Research, 2020, Volume 12, 127-136.	0.9	10
131	Personalized Assessment of Normal Tissue Radiosensitivity via Transcriptome Response to Photon, Proton and Carbon Irradiation in Patient-Derived Human Intestinal Organoids. Cancers, 2020, 12, 469.	1.7	9
132	Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma. Cancer Management and Research, 2020, Volume 12, 633-639.	0.9	6
133	The Role of ⁶⁸ Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. Journal of Nuclear Medicine, 2020, 61, 1331-1336.	2.8	106
134	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	0.6	42
135	Analysis of a Surgical Series of 21 Cerebral Radiation Necroses. World Neurosurgery, 2020, 137, e462-e469.	0.7	6
136	Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial. BMC Cancer, 2020, 20, 52.	1.1	8
137	Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. Scientific Reports, 2020, 10, 686.	1.6	11
138	A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases. Journal of Neuro-Oncology, 2020, 147, 607-618.	1.4	9
139	Comparison of GeneChip, nCounter, and Real-Time PCR–Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
140	Accelerated Partial Breast Irradiation: A New Standard of Care?. Breast Care, 2020, 15, 136-147.	0.8	14
141	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ⁻ve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	0.8	12
142	MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?. Frontiers in Oncology, 2020, 10, 615697.	1.3	6
143	First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany. Strahlentherapie Und Onkologie, 2020, 196, 691-698.	1.0	44
144	Molecular Imaging for Particle Therapy: Current Approach and Future Directions. Recent Results in Cancer Research, 2020, 216, 865-879.	1.8	0

#	Article	IF	CITATIONS
145	Helical tomotherapy in patients with leptomeningeal metastases. Cancer Management and Research, 2019, Volume 11, 401-409.	0.9	11
146	⁶⁸ Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. Journal of Nuclear Medicine, 2019, 60, 386-392.	2.8	468
147	⁶⁸ Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. Journal of Nuclear Medicine, 2019, 60, 234-240.	2.8	49
148	IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2569-2580.	3.3	94
149	Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck. Frontiers in Oncology, 2019, 9, 755.	1.3	2
150	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. Stem Cell Research, 2019, 40, 101536.	0.3	18
151	Carbon-ion irradiation overcomes HPV-integration/E2 gene-disruption induced radioresistance of cervical keratinocytes. Journal of Radiation Research, 2019, 60, 564-572.	0.8	4
152	Differential response of esophageal cancer cells to particle irradiation. Radiation Oncology, 2019, 14, 119.	1.2	9
153	Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiation Oncology, 2019, 14, 122.	1.2	9
154	Dosimetric validation of Monte Carlo and analytical dose engines with raster-scanning 1H, 4He, 12C, and 16O ion-beams using an anthropomorphic phantom. Physica Medica, 2019, 64, 123-131.	0.4	18
155	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Annals of Surgical Oncology, 2019, 26, 3892-3901.	0.7	29
156	Risen from the dead: Cardiac stereotactic ablative radiotherapy as last rescue in a patient with refractory ventricular fibrillation storm. HeartRhythm Case Reports, 2019, 5, 329-332.	0.2	50
157	Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution. Radiation Oncology, 2019, 14, 117.	1.2	46
158	Clinical applications of proton and carbon ion therapy. Seminars in Oncology, 2019, 46, 226-232.	0.8	62
159	Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy. Frontiers in Oncology, 2019, 9, 962.	1.3	35
160	Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation. Frontiers in Oncology, 2019, 9, 940.	1.3	20
161	Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience. Cancers, 2019, 11, 1705.	1.7	25
162	Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck. Radiation Oncology, 2019, 14, 194.	1.2	2

#	Article	IF	CITATIONS
163	Carbon ion and proton beam irradiation of a normal human TK6 lymphoblastoid cell line within a magnetic field of 1.0 tesla. Cancer Management and Research, 2019, Volume 11, 8327-8335.	0.9	3
164	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. Radiation Oncology, 2019, 14, 179.	1.2	11
165	Elective Node Irradiation With Integrated Boost to the Prostate Using Helical IMRT–Clinical Outcome of the Prospective PLATIN-1 Trial. Frontiers in Oncology, 2019, 9, 751.	1.3	6
166	Overcoming radioresistance in WiDr cells with heavy ion irradiation and radiosensitization by 2-deoxyglucose with photon irradiation. Clinical and Translational Radiation Oncology, 2019, 19, 52-58.	0.9	1
167	Overexpression of p16INK4a Serves as Prognostic Marker in Squamous Cell Vulvar Cancer Patients Treated With Radiotherapy Irrespective of HPV-Status. Frontiers in Oncology, 2019, 9, 891.	1.3	9
168	Active-Scanned Protons and Carbon Ions in Cancer Treatment of Patients With Cardiac Implantable Electronic Devices: Experience of a Single Institution. Frontiers in Oncology, 2019, 9, 798.	1.3	10
169	Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 803-811.	0.4	40
170	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. Journal of Contemporary Brachytherapy, 2019, 11, 312-319.	0.4	15
171	The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience. Oral Oncology, 2019, 97, 115-123.	0.8	10
172	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. Cancers, 2019, 11, 122.	1.7	25
173	<p>Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis</p> . Cancer Management and Research, 2019, Volume 11, 789-801.	0.9	35
174	<p>Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma – final results of the BRAIN-RT trial</p> . Cancer Management and Research, 2019, Volume 11, 4669-4676.	0.9	7
175	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patients—First Clinical Results From a Single Center. Frontiers in Oncology, 2019, 9, 384.	1.3	9
176	Impact of dimethyl sulfoxide on irradiation-related DNA double-strand-break induction, -repair and cell survival. Radiation and Environmental Biophysics, 2019, 58, 417-424.	0.6	9
177	Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers, 2019, 11, 709.	1.7	32
178	FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1754-1755.	3.3	58
179	Identification of KIF11 As a Novel Target in Meningioma. Cancers, 2019, 11, 545.	1.7	31
180	The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer. Strahlentherapie Und Onkologie, 2019, 195, 902-912.	1.0	13

#	Article	IF	CITATIONS
181	Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control. Cancers, 2019, 11, 379.	1.7	15
182	Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention. Journal of Nuclear Medicine, 2019, 60, 1421-1429.	2.8	281
183	<p>Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety</p> . Cancer Management and Research, 2019, Volume 11, 1155-1166.	0.9	15
184	Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T. Journal of Magnetic Resonance Imaging, 2019, 50, 1268-1277.	1.9	58
185	⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Journal of Nuclear Medicine, 2019, 60, 801-805.	2.8	874
186	Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlentherapie Und Onkologie, 2019, 195, 677-687.	1.0	13
187	Breast cancer occurrence after low dose radiotherapy of non-malignant disorders of the shoulder. Scientific Reports, 2019, 9, 5301.	1.6	8
188	Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer. Cancers, 2019, 11, 383.	1.7	6
189	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncology, The, 2019, 20, 728-740.	5.1	271
190	Re-irradiation in locally recurrent lung cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 725-733.	1.0	17
191	The role of organ―and functionâ€preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx. Head and Neck, 2019, 41, 2208-2214.	0.9	6
192	Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx. Oral Oncology, 2019, 91, 39-46.	0.8	25
193	Intrinsic and extrinsic tumor characteristics are of minor relevance for the efficacy of split-dose carbon ion irradiation in three experimental prostate tumors. Radiotherapy and Oncology, 2019, 133, 120-124.	0.3	4
194	Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. Radiation Oncology, 2019, 14, 34.	1.2	12
195	Dose-Limiting Organs at Risk in Carbon Ion Re-Irradiation of Head and Neck Malignancies: An Individual Risk-Benefit Tradeoff. Cancers, 2019, 11, 2016.	1.7	6
196	Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma. Frontiers in Oncology, 2019, 9, 1420.	1.3	9
197	Rare entities in head-and-neck cancer: salvage re-irradiation with carbon ions. Radiation Oncology, 2019, 14, 202.	1.2	6
198	Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers, 2019, 11, 1655.	1.7	42

#	Article	IF	CITATIONS
199	Human mesenchymal stem cells are resistant to UV-B irradiation. Scientific Reports, 2019, 9, 20000.	1.6	11
200	Dosimetric Impact of Interfractional Variations for Post-prostatectomy Radiotherapy to the Prostatic Fossa—Relevance for the Frequency of Position Verification Imaging and Treatment Adaptation. Frontiers in Oncology, 2019, 9, 1191.	1.3	5
201	Modeling the Effect of Hypoxia and DNA Repair Inhibition on Cell Survival After Photon Irradiation. International Journal of Molecular Sciences, 2019, 20, 6054.	1.8	12
202	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. Clinical Cancer Research, 2019, 25, 1505-1516.	3.2	67
203	High-resolution FLAIR MRI at 7 Tesla for treatment planning in glioblastoma patients. Radiotherapy and Oncology, 2019, 130, 180-184.	0.3	17
204	Large scale <i>in vivo</i> microâ€RNA loss of function screen identified miRâ€29a, miRâ€100 and miRâ€155 as modulators of radioresistance and tumorâ€stroma communication. International Journal of Cancer, 2019, 144, 2774-2781.	2.3	8
205	Determining RBE for development of lung fibrosis induced by fractionated irradiation with carbon ions utilizing fibrosis index and high-LET BED model. Clinical and Translational Radiation Oncology, 2019, 14, 25-32.	0.9	7
206	Synthetic phosphopeptides: From spike-in standards to affinity tools for protein-protein interaction studies. Analytical Biochemistry, 2019, 568, 73-77.	1.1	0
207	Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation. International Journal of Cancer, 2019, 144, 3160-3173.	2.3	13
208	Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. Tumori, 2019, 105, 174-180.	0.6	19
209	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	0.6	100
210	Robotic Radiosurgery for Brain Metastases Diagnosed With Either SPACE or MPRACE Sequence (CYBER-SPACE)—A Single-Center Prospective Randomized Trial. Neurosurgery, 2019, 84, 253-260.	0.6	8
211	Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight, 2019, 4, .	2.3	63
212	Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes Journal of Clinical Oncology, 2019, 37, 2012-2012.	0.8	3
213	Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial Journal of Clinical Oncology, 2019, 37, 2059-2059.	0.8	3
214	Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial Journal of Clinical Oncology, 2019, 37, 8543-8543.	0.8	0
215	Response rates and recurrence patterns after low-dose radiotherapy with 4†Gy in patients with low-grade lymphomas. Strahlentherapie Und Onkologie, 2018, 194, 454-461.	1.0	22
216	High control rates of proton†and carbonâ€ion–beam treatment with intensityâ€modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center. Cancer, 2018, 124, 2036-2044.	2.0	52

#	Article	IF	CITATIONS
217	Reâ€irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score—report of the Radiation Oncology Group (<scp>ROG</scp>) of the German Cancer Consortium (<scp>DKTK</scp>). Cancer Medicine, 2018, 7, 1742-1749.	1.3	34
218	A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. Journal of Nuclear Medicine, 2018, 59, 1423-1429.	2.8	453
219	Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. Journal of Nuclear Medicine, 2018, 59, 1415-1422.	2.8	522
220	The Radiation Resistance of Human Multipotent Mesenchymal Stromal Cells Is Independent of Their Tissue of Origin. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1259-1269.	0.4	26
221	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiotherapy and Oncology, 2018, 127, 121-127.	0.3	37
222	Prospective feasibility analysis of aÂnovel off-line approach for MR-guided radiotherapy. Strahlentherapie Und Onkologie, 2018, 194, 425-434.	1.0	23
223	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	0.6	32
224	Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices. Clinical Lung Cancer, 2018, 19, 340-345.	1.1	16
225	Intraoperative Electron Radiation Therapy inÂRetroperitoneal Sarcoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 516-527.	0.4	23
226	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
227	Heavy Charged Particles: Does Improved Precision and Higher Biological Effectiveness Translate to Better Outcome in Patients?. Seminars in Radiation Oncology, 2018, 28, 160-167.	1.0	49
228	Improving the modelling of irradiation-induced brain activation for in vivo PET verification of proton therapy. Radiotherapy and Oncology, 2018, 128, 101-108.	0.3	12
229	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
230	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24
231	Outcome and prognostic factors in single brain metastases from small-cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 98-106.	1.0	21
232	3D-Printed masks as a new approach for immobilization in radiotherapy - a study of positioning accuracy. Oncotarget, 2018, 9, 6490-6498.	0.8	26
233	Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget, 2018, 9, 28772-28783.	0.8	63
234	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	1.6	27

#	Article	IF	CITATIONS
235	Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Management and Research, 2018, Volume 10, 6563-6569.	0.9	31
236	Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity. Cancers, 2018, 10, 488.	1.7	15
237	Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution's Clinical Experience. Cancers, 2018, 10, 457.	1.7	13
238	Intraoperative Electron Radiation Therapy Combined with External Beam Radiation Therapy after Gross Total Resection in Extremity Soft Tissue Sarcoma: A European Pooled Analysis. Annals of Surgical Oncology, 2018, 25, 3833-3842.	0.7	13
239	Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta OncolA ³ gica, 2018, 57, 1713-1720.	0.8	20
240	Accelerated Hypofractionated Active Raster-Scanned Carbon Ion Radiotherapy (CIRT) for Laryngeal Malignancies: Feasibility and Safety. Cancers, 2018, 10, 388.	1.7	7
241	Persistence of radiation-induced aberrations in patients after radiotherapy with C-ions and IMRT. Clinical and Translational Radiation Oncology, 2018, 13, 57-63.	0.9	7
242	Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas. Radiation Oncology, 2018, 13, 154.	1.2	14
243	The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiation Oncology, 2018, 13, 134.	1.2	13
244	Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiotherapy and Oncology, 2018, 128, 274-282.	0.3	155
245	"Radiobiology of Proton Therapyâ€ŧ Results of an international expert workshop. Radiotherapy and Oncology, 2018, 128, 56-67.	0.3	85
246	Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma. Radiation Oncology, 2018, 13, 140.	1.2	20
247	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	1.2	34
248	Whole brain radiation therapy alone versus radiosurgery for patients with 1–10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. Trials, 2018, 19, 388.	0.7	25
249	Proton and helium ion radiotherapy for meningioma tumors: a Monte Carlo-based treatment planning comparison. Radiation Oncology, 2018, 13, 2.	1.2	36
250	Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial. Trials, 2018, 19, 59.	0.7	10
251	Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. Scientific Reports, 2018, 8, 7201.	1.6	33
252	Reserve stem cell population in intestinal crypts found to be consistently small by analysis of in vivo clonogenic assays with a biomathematical dynamic model. Radiotherapy and Oncology, 2018, 129, 595-599.	0.3	3

#	Article	IF	CITATIONS
253	Palliative Radiotherapy for Leptomeningeal Carcinomatosis–Analysis of Outcome, Prognostic Factors, and Symptom Response. Frontiers in Oncology, 2018, 8, 641.	1.3	32
254	A phase la/lb trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results Journal of Clinical Oncology, 2018, 36, 2518-2518.	0.8	14
255	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Journal of Clinical Oncology, 2018, 36, 6047-6047.	0.8	2
256	Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey. JMIR MHealth and UHealth, 2018, 6, e10916.	1.8	30
257	Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial. JMIR Research Protocols, 2018, 7, e70.	0.5	11
258	Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2 Journal of Clinical Oncology, 2018, 36, 12090-12090.	0.8	0
259	Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life. Radiology and Oncology, 2018, 52, 320-328.	0.6	2
260	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 750-755.	2.8	105
261	Effective user guidance in online interactive semantic segmentation. Proceedings of SPIE, 2017, , .	0.8	1
262	Radiation-induced toxicity after image-guided and intensity-modulated radiotherapy versus external beam radiotherapy for patients with spinal bone metastases (IRON-1): a study protocol for a randomized controlled pilot trial. Trials, 2017, 18, 98.	0.7	3
263	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	3.3	425
264	First clinical investigation of a 4D maximum likelihood reconstruction for 4D PET-based treatment verification in ion beam therapy. Radiotherapy and Oncology, 2017, 123, 339-345.	0.3	4
265	Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research, 2017, 23, 4170-4180.	3.2	37
266	⁶⁸ Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine, 2017, 58, 1943-1948.	2.8	81
267	Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. Journal of Neuro-Oncology, 2017, 134, 205-212.	1.4	28
268	Deciphering the Acute Cellular Phosphoproteome Response to Irradiation with X-rays, Protons and Carbon Ions. Molecular and Cellular Proteomics, 2017, 16, 855-872.	2.5	27
269	Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell LungÂCancer. Clinical Lung Cancer, 2017, 18, e267-e271.	1.1	12
270	Stability of Spinal Bone Lesions in Patients With Multiple Myeloma After Radiotherapy—A Retrospective Analysis of 130 Cases. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e99-e107.	0.2	7

#	Article	IF	CITATIONS
271	Sequential proton boost after standard chemoradiation for high-grade glioma. Radiotherapy and Oncology, 2017, 125, 266-272.	0.3	20
272	Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiotherapy and Oncology, 2017, 125, 317-324.	0.3	41
273	Phytotherapeutics oridonin and ponicidin show additive effects combined with irradiation in pancreatic cancer <i>in vitro</i> . Radiology and Oncology, 2017, 51, 407-414.	0.6	7
274	Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2017, 99, 912-920.	0.4	13
275	Differentiated resistance training of the paravertebral muscles in patients with unstable spinal bone metastasis under concomitant radiotherapy: study protocol for a randomized pilot trial. Trials, 2017, 18, 155.	0.7	7
276	Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?. Clinical and Translational Radiation Oncology, 2017, 7, 79-82.	0.9	6
277	Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy. Radiation Oncology, 2017, 12, 115.	1.2	17
278	Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer—Experiences from a Single Institution. Frontiers in Oncology, 2017, 7, 215.	1.3	9
279	Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiation Oncology, 2017, 12, 208.	1.2	75
280	Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model. Radiation Oncology, 2017, 12, 172.	1.2	16
281	Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas. Radiation Oncology, 2017, 12, 174.	1.2	18
282	Treatment planning for MLC based robotic radiosurgery for brain metastases: plan comparison with circular fields and suggestions for planning strategies. Current Directions in Biomedical Engineering, 2017, 3, 151-154.	0.2	5
283	Effective user interaction in online interactive semantic segmentation of glioblastoma magnetic resonance imaging. Journal of Medical Imaging, 2017, 4, 1.	0.8	1
284	Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy. Radiology and Oncology, 2017, 52, 189-194.	0.6	4
285	NIR-Cyanine Dye Linker: a Promising Candidate for Isochronic Fluorescence Imaging in Molecular Cancer Diagnostics and Therapy Monitoring. Theranostics, 2016, 6, 131-141.	4.6	22
286	Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?. Stem Cells International, 2016, 2016, 1-10.	1.2	12
287	Stability, Prognostic Factors and Survival of Spinal Bone Metastases in Malignant Melanoma Patients after Palliative Radiotherapy. Tumori, 2016, 102, 156-161.	0.6	27
288	Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams. Oncotarget, 2016, 7, 56676-56689.	0.8	72

#	Article	IF	CITATIONS
289	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wildâ€type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	2.3	18
290	Rasterâ€scanned intensityâ€controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. Head and Neck, 2016, 38, E1445-51.	0.9	13
291	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology. 2016. 121. 364-373.	0.3	130
292	Initial clinical evaluation of PETâ€based ion beam therapy monitoring under consideration of organ motion. Medical Physics, 2016, 43, 975-982.	1.6	11
293	Mesenchymal stem cells are sensitive to bleomycin treatment. Scientific Reports, 2016, 6, 26645.	1.6	46
294	Resistance training concomitant to radiotherapy of spinal bone metastases – survival and prognostic factors of a randomized trial. Radiation Oncology, 2016, 11, 97.	1.2	39
295	Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study—The IPI Trial. International Journal of Radiation Oncology Biology Physics, 2016, 95, 435-443.	0.4	49
296	Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors. Cancer Letters, 2016, 378, 97-103.	3.2	41
297	Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer. Strahlentherapie Und Onkologie, 2016, 192, 895-904.	1.0	21
298	Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives. Visceral Medicine, 2016, 32, 172-177.	0.5	48
299	Radiogenomics of Glioblastoma: Machine Learning–based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	3.6	236
300	Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. Lung Cancer, 2016, 101, 76-81.	0.9	31
301	Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin. Scientific Reports, 2016, 6, 20035.	1.6	33
302	Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution. Radiation Oncology, 2016, 11, 80.	1.2	12
303	Survival and prognostic factors in patients with stable and unstable spinal bone metastases from solid tumors: a retrospective analysis of 915 cases. BMC Cancer, 2016, 16, 528.	1.1	4
304	Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis. Radiation Oncology, 2016, 11, 17.	1.2	38
305	High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer. Strahlentherapie Und Onkologie, 2016, 192, 458-466.	1.0	12
306	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127

#	Article	IF	CITATIONS
307	Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases. Radiotherapy and Oncology, 2016, 119, 22-29.	0.3	31
308	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
309	Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Letters, 2016, 374, 75-84.	3.2	21
310	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	3.0	283
311	Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC). Lung Cancer, 2016, 91, 41-47.	0.9	6
312	Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-House Analysis System. Technology in Cancer Research and Treatment, 2016, 15, 348-354.	0.8	4
313	68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 34-41.	3.3	194
314	Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 112-119.	0.4	46
315	High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. Radiotherapy and Oncology, 2016, 118, 272-280.	0.3	77
316	Clinical outcome after multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence Journal of Clinical Oncology, 2016, 34, 6028-6028.	0.8	1
317	Umbrella protocol for phase I/lla trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²) Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	0.8	4
318	Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific α/β-Values for Patients with Non-Resectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0164473.	1.1	5
319	Evaluation of Dosimetric Robustness of Carbon Ion Boost Therapy for Anal Carcinoma. International Journal of Particle Therapy, 2016, 3, 382-391.	0.9	1
320	Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. European Journal of Medical Research, 2015, 20, 64.	0.9	34
321	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation Oncology, 2015, 10, 146.	1.2	14
322	Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view. Radiation Oncology, 2015, 10, 147.	1.2	2
323	A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). BMC Cancer, 2015, 15, 988.	1.1	18
324	Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer. Radiation Oncology, 2015, 10, 144.	1.2	15

#	Article	IF	CITATIONS
325	Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiation Oncology, 2015, 10, 267.	1.2	58
326	Patient data-based Monte Carlo simulation of in-beam single-ring OpenPET imaging. , 2015, , .		1
327	Combined intensityâ€modulated radiotherapy plus rasterâ€scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer, 2015, 121, 3001-3009.	2.0	81
328	First Steps Toward Ultrasound-Based Motion Compensation for Imaging and Therapy: Calibration with an Optical System and 4D PET Imaging. Frontiers in Oncology, 2015, 5, 258.	1.3	7
329	Correlation of Particle Traversals with Clonogenic Survival Using Cell-Fluorescent Ion Track Hybrid Detector. Frontiers in Oncology, 2015, 5, 275.	1.3	9
330	Re-irradiation of adenoid cystic carcinoma: Analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiotherapy and Oncology, 2015, 114, 182-188.	0.3	75
331	Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncology, The, 2015, 16, e93-e100.	5.1	423
332	In vivo measurement of dose distribution in patients' lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer. Journal of Radiation Research, 2015, 56, 239-247.	0.8	7
333	Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer. Radiotherapy and Oncology, 2015, 114, 173-181.	0.3	43
334	Mesenchymal stem cells – A new hope for radiotherapy-induced tissue damage?. Cancer Letters, 2015, 366, 133-140.	3.2	83
335	Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis. Radiation Oncology, 2015, 10, 62.	1.2	22
336	Carbon Ion irradiation in the treatment of grossly incomplete or unresectable malignant peripheral nerve sheaths tumors: acute toxicity and preliminary outcome. Radiation Oncology, 2015, 10, 109.	1.2	11
337	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1084-1092.	0.4	64
338	Clinical results and toxicity for short-course preoperative radiotherapy and total mesorectal excision in rectal cancer patients. Journal of Radiation Research, 2015, 56, 169-176.	0.8	9
339	Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. BMC Cancer, 2015, 15, 537.	1.1	10
340	Loss of SOX2 expression induces cell motility via vimentin upâ€regulation and is an unfavorable risk factor for survival ofÂhead and neck squamous cell carcinoma. Molecular Oncology, 2015, 9, 1704-1719.	2.1	60
341	Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of Radiation Research, 2015, 56, 742-749.	0.8	20
342	COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 37-46.	0.4	75

#	Article	IF	CITATIONS
343	The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 197-209.	3.3	866
344	Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials Journal of Clinical Oncology, 2015, 33, 1008-1008.	0.8	21
345	Mesenchymal stem cells are resistant to carbon ion radiotherapy. Oncotarget, 2015, 6, 2076-2087.	0.8	39
346	Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 127-42.	1.0	24
347	For the Next Trick: New Discoveries in Radiobiology Applied to Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e95-e99.	1.8	22
348	Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer. Radiotherapy and Oncology, 2014, 113, 331-336.	0.3	54
349	Independent calculation of dose distributions for helical tomotherapy using a conventional treatment planning system. Medical Physics, 2014, 41, 081709.	1.6	2
350	Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: First longâ€ŧerm results. Cancer, 2014, 120, 3410-3417.	2.0	124
351	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology. 2014. 113. 317-323.	0.3	141
352	Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Computer Methods and Programs in Biomedicine, 2014, 114, 206-217.	2.6	39
353	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research, 2014, 20, 6304-6313.	3.2	111
354	Hypofractionated IMRT of the Prostate Bed After Radical Prostatectomy: Acute Toxicity in the PRIAMOS-1 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 90, 926-933.	0.4	31
355	Glioblastoma Recurrence Patterns After Radiation Therapy With Regard to the Subventricular Zone. International Journal of Radiation Oncology Biology Physics, 2014, 90, 886-893.	0.4	104
356	Chordoma: an assessment of future treatment and management strategies. Expert Opinion on Orphan Drugs, 2014, 2, 557-565.	0.5	1
357	Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma Journal of Clinical Oncology, 2014, 32, 2006-2006.	0.8	2
358	LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC) Journal of Clinical Oncology, 2014, 32, 4081-4081.	0.8	9
359	START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy Journal of Clinical Oncology, 2014, 32, TPS7608-TPS7608.	0.8	3
360	Effects of resistance training on fatigue and quality of life in breast cancer patients undergoing radiotherapy Journal of Clinical Oncology, 2014, 32, 9534-9534.	0.8	1

#	Article	IF	CITATIONS
361	Improvement of surgical results for pancreatic cancer. Lancet Oncology, The, 2013, 14, e476-e485.	5.1	307
362	Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma–a randomized trial. Radiation Oncology, 2013, 8, 234.	1.2	13
363	Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiotherapy and Oncology, 2013, 109, 487-492.	0.3	74
364	Mesenchymal Stem Cells Retain Their Defining Stem Cell Characteristics After Exposure to Ionizing Radiation. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1171-1178.	0.4	70
365	Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis. Radiotherapy and Oncology, 2013, 108, 132-135.	0.3	42
366	Relative Biological Effectiveness of Carbon lons in a Rat Prostate Carcinoma In Vivo: Comparison of 1, 2, and 6 Fractions. International Journal of Radiation Oncology Biology Physics, 2013, 86, 450-455.	0.4	21
367	In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. Journal of Radiation Research, 2013, 54, i113-i119.	0.8	36
368	Current status of 4D offline PET-based treatment verification at the Heidelberg Ion-Beam Therapy Center. , 2013, , .		1
369	Primary Radiotherapy with Endobronchial High-Dose-Rate Brachytherapy Boost for Inoperable Lung Cancer: Long-Term Results. Tumori, 2013, 99, 183-190.	0.6	9
370	Reversible posterior leucoencephalopathy syndrome (RPLS) associated with pazopanib Journal of Clinical Oncology, 2013, 31, e15574-e15574.	0.8	0
371	Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiation Oncology, 2012, 7, 130.	1.2	34
372	APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma Journal of Clinical Oncology, 2012, 30, 2034-2034.	0.8	7
373	Feasibility of 6 months of maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck (HNC) Journal of Clinical Oncology, 2012, 30, e16033-e16033.	0.8	0
374	Relative Biological Effectiveness of Carbon Ions for Local Tumor Control of a Radioresistant Prostate Carcinoma in the Rat. International Journal of Radiation Oncology Biology Physics, 2011, 79, 239-246.	0.4	45
375	Post-therapeutical \hat{l}^2 +-activity measurements in comparison to simulations towards in-vivo verification of ion beam therapy. , 2011, , .		7
376	Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer, 2010, 10, 96.	1.1	56
377	Particle therapy at the Heidelberg Ion Therapy Center (HIT) – Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiotherapy and Oncology, 2010, 95, 41-44.	0.3	119
378	Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncológica, 2010, 49, 1132-1140.	0.8	93

#	Article	IF	CITATIONS
379	Particle therapy — Physical, technical and clinical aspects. European Journal of Cancer, 2009, 45, 381-382.	1.3	0
380	Carbon ion radiotherapy of skull base chondrosarcomas. International Journal of Radiation Oncology Biology Physics, 2007, 67, 171-177.	0.4	177
381	Effectiveness of Carbon Ion Radiotherapy in the Treatment of Skull-Base Chordomas. International Journal of Radiation Oncology Biology Physics, 2007, 68, 449-457.	0.4	276
382	Radiation tolerance of the rat spinal cord after 6 and 18 fractions of photons and carbon ions: Experimental results and clinical implications. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1488-1497.	0.4	84
383	External Beam Radiotherapy in the Treatment of Male Breast Carcinoma: Patterns of Failure in a Single Institute Experience. Tumori, 2005, 91, 151-155.	0.6	18
384	External beam radiotherapy in the treatment of male breast carcinoma: patterns of failure in a single institute experience. Tumori, 2005, 91, 151-5.	0.6	4
385	MDR-1 Recognition by Cytotoxic T Cells Blood, 2004, 104, 1346-1346.	0.6	0
386	High Efficacy of Fractionated Stereotactic Radiotherapy of Large Base-of-Skull Meningiomas: Long-Term Results. Journal of Clinical Oncology, 2001, 19, 3547-3553.	0.8	264
387	Postoperative radiotherapy of astrocytomas. Journal of Surgical Oncology, 2001, 20, 13-23.	1.4	38
388	Adjuvant treatment of brain metastases. Journal of Surgical Oncology, 2001, 20, 50-56.	1.4	67
389	Improving Chemoradiotherapy in Rectal Cancer. Oncologist, 2001, 6, 29-34.	1.9	46
390	Patient position verification using CT images. Medical Physics, 1999, 26, 941-948.	1.6	13
391	Synergistic interaction of ultrasonic shock waves and hyperthermia in the dunning prostate tumor r3327-at1. , 1999, 82, 84-91.		15